|
1
|
Elderon L and Whooley MA: Depression and
Cardiovascular Disease. Prog Cardiovasc Dis. 55:511–523. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rugulies R: Depression as a predictor for
coronary heart disease. A review and meta-analysis. Am J Prev Med.
23:51–61. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramasubbu R and Patten SB: Effect of
depression on stroke morbidity and mortality. Can J Psychiatry.
48:250–257. 2003.PubMed/NCBI
|
|
4
|
Luvai A, Mbagaya W, Hall AS and Barth JH:
Rosuvastatin: A review of the pharmacology and clinical
effectiveness in cardiovascular disease. Clin Med Insights Cardiol.
6:17–33. 2012.PubMed/NCBI
|
|
5
|
You H, Lu W, Zhao S, Hu Z and Zhang J: The
relationship between statins and depression: A review of the
literature. Expert Opin Pharmacother. 14:1467–1476. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guthrie RM and Martin DR: The safety of
rosuvastatin: Effect of renal and hepatic function. Expert Opin
Drug Saf. 6:573–581. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chan KL, Dumesnil JG, Tam J, Ni A and Teo
K: Effect of rosuvastatin on C-reactive protein and progression of
aortic stenosis. Am Heart J. 161:1133–1139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cohen DE, Anania FA and Chalasani N:
National Lipid Association Statin Safety Task Force Liver Expert
Panel: An assessment of statin safety by hepatologists. Am J
Cardiol. 97:77C–81C. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soran H and Durrington P: Rosuvastatin:
Efficacy, safety and clinical effectiveness. Expert Opin
Pharmacother. 9:2145–2160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jian W and Davidson JR: Antidepressant
therapy in patients with ischemic heart disease. Am Heart J.
150:871–881. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leucht C, Huhn M and Leucht S:
Amitriptyline versus placebo for major depressive disorder.
Cochrane Database Syst Rev. 12:CD0091382012.PubMed/NCBI
|
|
12
|
von Moltke LL, Greenblatt DJ and Shader
RI: Clinical pharmacokinetics of antidepressants in the elderly.
Therapeutic implications. Clin Pharmacokinet. 24:141–160. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roose SP, Glassman AH, Attia E, Woodring
S, Giardina EG and Bigger JT Jr: Cardiovascular effects of
fluoxetine in depressed patients with heart disease. Am J
Psychiatry. 155:660–665. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brambilla P, Cipriani A, Hotopf M and
Barbui C: Side-effect profile of fluoxetine in comparison with
other SSRIs, tricyclic and newer antidepressants: A meta-analysis
of clinical trial data. Pharmacopsychiatry. 38:69–77. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Castiella A and Arenas J: Fluoxetine
hepatotoxicity. Am J Gastroenterol. 89:458–459. 1994.PubMed/NCBI
|
|
16
|
Inkielewicz-Stępniak I: Impact of
fluoxetine on liver damage in rats. Pharmacol Rep. 63:441–447.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mavrides N and Nemeroff C: Treatment of
depression in cardiovascular disease. Depress Anxiety. 30:328–341.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Herbet M, Gawrońska-Grzywacz M and
Jagiełło-Wójtowicz E: The influence of combined treatment of
simvastatin and amitriptyline on some biochemical parameters in rat
serum. Ann UMCS Sect DDD. 23:121–127. 2010.
|
|
19
|
Herbet M, Gawrońska-Grzywacz M, Kwiatek K
and Jagiełło-Wójtowicz E: Evaluation of selected biochemical
parameters in the serum of rats pretreated with simvastatin,
doxepin or their combination. Ann UMCS Sect DDD. 24:107–113.
2011.
|
|
20
|
Karnik NS and Maldonaldo JR:
Antidepressant and statin interactions: A review and case report of
simvastatin and nefazodone-induced rhabdomyolysis and
transaminitis. Psychosomatics. 46:565–568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kasiske BL, Wanner C and O'Neill WC: An
Assessment of statin safety by nephrologists. Am J Cardiol.
97:82C–85C. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Levy NB, Blumenfield M, Beasley CM Jr,
Dubey AK, Solomon RJ, Todd R, Goodman A and Bergstrom RR:
Fluoxetine in depressed patients with renal failure and in
depressed patients with normal kidney function. Gen Hosp
Psychiatry. 18:8–13. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blumenfield M, Levy NB, Spinowitz B,
Charytan C, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A
and Bergstrom RF: Fluoxetine in depressed patients on dialysis. Int
J Psychiatry Med. 27:71–80. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vasudevan AR, Hamirani YS and Jones PH:
Safety of statins: Effects on muscle and the liver. Cleve Clin J
Med. 72:990–993. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang LS, Liu ZX, Lü W and Hu XY: Effects
of statins on the liver: Clinical analysis of patients with
ischemic stroke. Chin Med J (Engl). 124:897–900. 2011.PubMed/NCBI
|
|
26
|
Wille SM, Cooreman SG, Neels HM and
Lambert WE: Relevant issues in the monitoring and the toxicology of
antidepressants. Crit Rev Clin Lab Sci. 45:25–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wen B, Ma L and Zhu M: Bioactivation of
the tricyclic antidepressant amitriptyline and its metabolite
nortriptyline to arene oxide intermediates in human liver
microsomes and recombinant P450s. Chem Biol Interact. 173:59–67.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Apella D, Bruguera M, Figueras A and
Laporte J: Fluoxetine-induced hepatitis: Why is postmarketing
surveillance needed? Eur J Clin Pharmacol. 55:545–546. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mandrioli R, Forti GC and Raggi MA:
Fluoxetine metabolism and pharmacological interactions: The role of
cytochrome P450. Curr Drug Metab. 7:127–133. 2006. View Article : Google Scholar : PubMed/NCBI
|
